If they get enough money to get through a pivotal/registrational trial to completion, and subsequentially get FDA approval, they will need to partner or sell the business.
I have no faith in this company's ability to scale out commercial operations. Perhaps I would give them more credit if they were able to sell a meaningful amount of CardioCel given the investment ($) that was poured into that. I hope they know this and aren't going to be driven by ego to go it alone.
I might sound like I am sour (because I am) but I generally want this company to be successful and if the product is as good as they claim it will be a good outcome for patients too.
If they get enough money to get through a pivotal/registrational...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.25 |
Change
-0.250(1.61%) |
Mkt cap ! $322.3M | |||
| Open | High | Low | Value | Volume |
| $15.50 | $15.50 | $14.80 | $140.4K | 9.315K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 297 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.25 | 1300 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |